Kintara Therapeutics

Kintara Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of new cancer therapies. Its product pipeline includes VAL-083 and REM-001. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.

SAN DIEGO , June 3, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that the Company received written notification from the Listing Qualification Department of The Nasdaq Stock Market LLC ("Nasdaq") granting the Company's request for a 180-day extension to regain compliance with Nasdaq's minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The Company now has until November 28, 2022 to meet the requirement.

Kintara Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement

SAN DIEGO , May 27, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that the VAL-083 treatment arm in the Global Coalition for Adaptive Research (GCAR) registrational Phase 2/3 clinical trial for glioblastoma (GBM), titled Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE), has activated its first European site, University Hospital Zurich in Zurich, Switzerland. GBM AGILE is currently active at 44 clinical sites in the United States and Canada as of May 26, 2022.

Kintara Announces First European Site Activation in Switzerland in GCAR Phase 2/3 Clinical Trial for Glioblastoma

Foresight Autonomous Hlds

Imperial Petroleum

Mullen Automotive

ObsEva

Regulus Therapeutics

These penny stocks all have 10x potential or greater during the remainder of 2022. They are risky but relatively straightforward.

7 Penny Stocks With 10x Potential This Year

SAN DIEGO , May 13, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal third quarter ended March 31, 2022 and provided a corporate update. CORPORATE HIGHLIGHTS AND RECENT DEVELOPMENTS Closed a registered direct financing with certain institutional investors pursuant to which the Company received approximately $7.9 million in net proceeds after deducting placement agent fees and other offering expenses payable by the Company (April).

Kintara Therapeutics Announces Fiscal 2022 Third Quarter Financial Results and Provides Corporate Update

Acutus Medical

Cosmos Holdings

Here's what you need to know about trading penny stocks on April 27th The post Best Penny Stocks to Buy Today? 3 Climbing In Morning Trading  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy Today? 3 Climbing In Morning Trading

Hycroft Mining Holding Corporation

RLX Technology

Are these under $2 penny stocks on your watchlist right now? The post Best Penny Stocks to Buy Under $2?

Best Penny Stocks to Buy Under $2? 3 to Watch in May

SAN DIEGO , April 26, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that President and CEO Robert E. Hoffman will present a corporate overview at the Planet MicroCap Showcase 2022.

Kintara Therapeutics to Present at the Planet MicroCap Showcase 2022

SAN DIEGO , April 14, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies today announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules with institutional investors for the purchase and sale of 16,226,416 shares of the Company's common stock (the "Shares") and warrants to purchase 16,226,416 shares of the Company's common stock (the "Warrants"), at a combined purchase price of $0.53 per Share and related Warrant, for gross proceeds of approximately $8.6 million, before deducting fees and other offering expenses. The Warrants have an exercise price of $0.41 per share, are exercisable immediately and expire five years from the date of issuance.

Kintara Announces Closing of $8.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SAN DIEGO , April 12, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of 16,226,416 shares of the Company's common stock (the "Shares") and warrants to purchase 16,226,416 shares of the Company's common stock (the "Warrants") at a combined purchase price of $0.53 per Share and related Warrant in a registered direct offering priced at-the-market under Nasdaq rules for gross proceeds of approximately $8.6 million, before deducting fees and other offering expenses. The Warrants will have an exercise price of $0.41 per share, will be exercisable immediately and will expire five years from the date of issuance.

Kintara Announces $8.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

AnPac Bio-Medical Science Co

Vinco Ventures

Check these three penny stocks out in April 2022 The post Popular Penny Stocks to Buy in April? 3 to Watch Right Now  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Popular Penny Stocks to Buy in April? 3 to Watch Right Now

Kintara Therapeutics (NASDAQ:KTRA) Inc presented data at the 2022 American Association for Cancer Research (AACR) Annual Meeting. The San Diego, California-based company is developing novel cancer therapies for patients with unmet medical needs, including VAL-083 for Glioblastoma Multiforme (GBM) and REM-001 for Cutaneous Metastatic Breast Cancer (CMBC).

Kintara Therapeutics presents data on VAL-083 at the 2022 American Association for Cancer Research Annual Meeting

SAN DIEGO , April 11, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announces that it has presented data at the 2022 American Association for Cancer Research (AACR) Annual Meeting. Data Presentation: Track 24: Experimental and Molecular Therapeutics Session PO.ET02.01 - Mechanisms of Drug Action 1 1843 / 15 - Dianhydrogalactitol (VAL-083) for the Treatment of Glioblastoma Multiforme (GBM): Impact of Glucose Transporters for Crossing the Blood Brain Barrier (BBB) (Presentation Time: Monday, April 11, 2022 - 1:30 p.m.

Kintara Therapeutics Presents Data at the 2022 American Association for Cancer Research Annual Meeting

SAN DIEGO , March 22, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announces that President and CEO Robert Hoffman will participate at the Maxim Group 2022 Virtual Growth Conference, which is being held on March 28-30, 2022. Mr. Hoffman will present a corporate overview which will become available on Monday, March 28, 2022 at 9:00 a.m.

Kintara Therapeutics to Present at the Maxim Group 2022 Virtual Growth Conference

SAN DIEGO , March 15, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announces that it will be presenting data at the 2022 American Association for Cancer Research (AACR) Annual Meeting.  The AACR 2022 Annual Meeting will be held from April 8 through April 13, 2022 in New Orleans.

Kintara Therapeutics Announces Data Presentation at the 2022 American Association for Cancer Research Annual Meeting

SAN DIEGO, Feb. 11, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal second quarter ended December 31, 2021 and provided a corporate update. CORPORATE HIGHLIGHTS AND RECENT DEVELOPMENTS Received notice of the U.S. Patent and Trademark Office's issuance of United States Patent No.

Kintara Therapeutics Announces Fiscal 2022 Second Quarter Financial Results and Provides Corporate Update

SAN DIEGO, Feb. 4, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its President and Chief Executive Officer, Robert E. Hoffman will present a corporate overview at the BIO CEO & Investor Conference, which is being held on February 14 – 17, 2022 at the New York Marriott Marquis in New York City, NY.

Kintara Therapeutics to Present at BIO CEO & Investor Conference on February 15, 2022

SAN DIEGO, Feb. 3, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that the U.S. Patent and Trademark Office has issued to Kintara United States Patent No. 11,234,955 covering a method of treating brain tumors including glioblastoma (GBM), medulloblastoma, and cancer brain tumor stem cells that has O6-methylguanine-DNA methyltransferase (MGMT)-driven drug resistance.

Kintara Therapeutics Announces Issuance of New US Patent Related to VAL-083 and MGMT Resistance: Implications for Targeting Brain Tumor Stem Cells

Kintara Therapeutics Inc has announced a multi-year research grant from Luxembourg National Research Fund (FNR) and Cancer Foundation Luxembourg to support the research of its VAL-083 program to treat glioblastoma (GBM), an aggressive brain cancer.  The grant has been awarded to Dr. Anna Golebiewska, who is co-leading the NORLUX Neuro-Oncology laboratory with Professor Simone Niclou at the Luxembourg Institute of Health.

Kintara Therapeutics announces multi-year research grant to support research of its VAL-083 program to treat glioblastoma

SAN DIEGO, Jan. 12, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that a multiyear research grant from Luxembourg National Research Fund (FNR) and Cancer Foundation Luxembourg has been awarded to Doctor Anna Golebiewska Ph.D., co-leading the NORLUX Neuro-Oncology laboratory with Professor Simone Niclou at the Luxembourg Institute of Health.

Kintara Announces Grant from Luxembourg National Research Fund and Cancer Foundation Luxembourg to Support VAL-083's Mechanism of Action Research in Glioblastoma

SAN DIEGO, Jan. 5, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its Chief Executive Officer, Robert E. Hoffman will present at the H.C.

Kintara Therapeutics to Present at the H.C. Wainwright Bioconnect 2022 Virtual Conference

SAN DIEGO, Dec. 7, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its Chief Executive Officer, Robert E. Hoffman, will present a corporate overview at the MedInvest Oncology Investor Conference, which is being held virtually on December 7 – 10, 2021.

Kintara Therapeutics to Present at the MedInvest Oncology Investor Conference on December 9, 2021

Kintara Therapeutics (NASDAQ:KTRA) Inc announced its first international site activation in its Global Coalition for Adaptive Research (GCAR) registrational Phase 2/3 clinical trial for glioblastoma multiforme (GBM). The treatment arm was activated in Canada at Toronto's Sunnybrook Health Sciences Centre.

Kintara Therapeutics announces first international site activation in its Phase 2/3 clinical trial for glioblastoma multiforme

SAN DIEGO, Nov. 30, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that the VAL-083 treatment arm in the Global Coalition for Adaptive Research (GCAR) registrational Phase 2/3 clinical trial for glioblastoma multiforme (GBM) has been activated at its first Canadian site, Sunnybrook Health Sciences Centre in Toronto. The Kintara treatment arm is also currently actively recruiting at 30 U.S. sites as of November 24, 2021.

Kintara Announces First International Site Activation in GCAR Phase 2/3 Clinical Trial for Glioblastoma

Kintara Therapeutics (NASDAQ:KTRA) Inc., a biopharmaceutical company focused on the development of new solid tumor cancer therapies, has revealed data from two scientific posters for its Phase 2 clinical studies of VAL-083, the company's lead compound for the treatment of glioblastoma multiforme (GBM), a lethal brain cancer and other solid tumors. The data is being presented at the two-day 26th annual scientific meeting of the Society for Neuro-Oncology (SNO) starting on November 18, 2021, in Boston.

Kintara presents updates on two Phase 2 clinical studies at the 2021 Society for Neuro-Oncology annual meeting.

SAN DIEGO, Nov. 18, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced data from two scientific posters for its Phase 2 clinical studies of VAL-083, the Company's lead compound for the treatment of glioblastoma multiforme (GBM).  The data are being presented at the 26th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) being held in Boston on November 18-21, 2021.

News for Kintara Therapeutics Stock (KTRA)